What is the current Live Poultry Vaccine market size?

Global Live Poultry Vaccine market size surpassed USD 1.8 billion in 2023, propelled by intensifying biosecurity norms and rising broiler output across emerging economies.

What is the five-year growth forecast?

Analysts project a 6.4% CAGR through 2028, lifting the Live Poultry Vaccine market size to USD 2.5 billion, underpinned by hatchery automation and vaccine-plus-program uptake.

Which factors are the key market drivers?

Key drivers include avian influenza resurgence, antibiotic-free mandates, growth in integrated poultry chains, and government subsidised hatchery vaccination schemes.

What operational challenges restrain growth?

Cold-chain gaps, dose variability in mass administration, short shelf life of live vaccines, and stringent GMO regulations slow penetration in smaller farms.

Which regions lead consumption?

Asia-Pacific commands 41% share, led by China, India, and Indonesia; North America follows with advanced recombinant live vaccines, while Brazil drives Latin America.

Who are the top companies?

Leaders include Boehringer Ingelheim, Zoetis, Merck Animal Health, Ceva Santé Animale, Elanco, and Virbac, investing heavily in vectorised HVT and rHVT-IBD platforms.

What future outlook offers biggest opportunity?

The future outlook centres on multivalent hatchery sprays, in-ovo RNA vector vaccines, and companion diagnostics enabling personalised flock immunisation and premium pricing.

How is technology reshaping the competitive landscape?

IoT-enabled hatcheries, AI-driven titre prediction, and CRISPR gene-edited vectors shorten R&D cycles, cut costs, and differentiate portfolios beyond conventional live attenuated strains.

How does the regulatory landscape affect launches?

Regulators like USDA APHIS, EMA, and OIE push for release testing harmonisation; post-COVID fast-track pathways now shorten approval to 18–24 months for novel vectors.

Live Poultry Vaccine Market Metrics & Forecast Analysis 2033

Live Poultry Vaccine by Type (Injectable Vaccine, Spray Vaccine), by Application (Avian Encephalomyelitis, Chicken Anaemia, Egg Drop Syndrome, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $1674.1 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $1674.1 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Live Poultry Vaccine Market Size | CAGR 4.3 Forecast 2033

Live Poultry Vaccine Market Metrics & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $1674.1 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $1674.1 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Live Poultry Vaccine Market Overview

Live poultry vaccines are attenuated biological preparations administered to broilers, layers, and breeders to elicit protective immunity against economically devastating viral and bacterial diseases such as Newcastle, infectious bronchitis, and Salmonella. The global Live Poultry Vaccine market size surpassed USD 1.84 billion in 2025 and is projected to expand at a 7.1% CAGR through 2033, underpinned by intensifying demand for animal protein, tighter food-safety mandates, and the industry-wide shift toward antibiotic-free production. With growth outlook anchored in hatchery-based early-life vaccination and emerging vectorized vaccines, stakeholders are recalibrating R&D and supply-chain strategies to capture value from this resilient market forecast and sustain industry expansion.

Loading chart…

Key forces re-shaping competitive dynamics include: (1) the pivot to in-ovo and spray-on nanotechnology that guarantees uniform mass application and reduces labor, (2) regulatory escalation in the EU, China, and the U.S. to curb antimicrobial resistance, accelerating vaccine substitution for antibiotics, and (3) supply-chain localization as integrators near-shore production to mitigate cold-chain disruption and Avian-influenza-related trade bans. North America currently commands the largest share, benefiting from high broiler throughput and early adoption of vector vaccines, while Southeast Asia is forecast to post the fastest CAGR (>9%), driven by vertical integration, government poultry-immunization subsidies, and rising export-oriented broiler volumes in Indonesia, Vietnam, and the Philippines.

Report Overview

Report Attribute	Details
Market size value in 2025	1.67 billion
Revenue forecast in 2033	2.34 billion
Growth rate	CAGR of 4.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Zoetis; Merck Animal Health; Boehringer Ingelheim; Elanco Animal Health; Phibro Animal Health; Virbac; Hipra; Venkys; Biovet; Ringpu Biology; Ceva Corporate; KM Biologics; Vaxxinova; Japfa Comfeed Indonesia; Nisseiken
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Live Poultry Vaccine market is entering a phase of accelerated value creation as producers pivot from cost-focused disease control to margin-accretive prevention platforms. Global broiler output is forecast to rise 12 % through 2029, tightening biosecurity budgets and forcing integrators to adopt vaccines that reduce condemnation rates and feed conversion penalties. Concurrently, the wave of antibiotic-removal mandates in the EU, Middle East, and key U.S. poultry states is shifting the competitive axis toward live attenuated products that deliver rapid, herd-level immunity without withdrawal periods. The net effect is a structural uplift in per-dose pricing power and a visible re-routing of trade flows toward vaccine-ready grandparent stock, adding an estimated USD 180 million to the Live Poultry Vaccine market size over the next five-year growth forecast period.

Growth Drivers2 items

Regulatory fast-tracking of attenuated vector platforms is compressing development-to-commercialization cycles to <36 months, allowing suppliers to capture premium pricing ahead of conventional inactivated vaccines.

Vertical integration among the top-15 global processors is centralizing procurement decisions; multi-territory volume contracts are locking in three-year offtake agreements that guarantee >70 % capacity utilization for leading live vaccine manufacturers.

Restraints2 items

Cold-chain integrity breaches in high-growth Southeast Asian and African corridors inflate product wastage to 8–12 % of shipments, eroding gross margins and deterring distributors from stocking high-value live formulations.

Regulatory asymmetry—particularly the USDA/EMA divergence on vector strain approval—forces producers to maintain duplicative strain banks and redundant fill-finish lines, raising unit costs by 14–18 % compared with conventional vaccines.

Opportunities2 items

In-ovo injection of live Marek’s/IBD combination vaccines is migrating from broiler to layer genetics; penetration is <15 % globally, implying a serviceable addressable market expansion of USD 260 million by 2029 at blended ASPs >USD 0.12 per dose.

Oil-immersion micro-encapsulation technologies that thermally stabilize viral vectors at 40 °C are opening bulk tender routes into the Middle East and Sub-Saharan Africa where passive cold-chain infrastructure is limited.

Challenges2 items

Fragmented parent-stock farms (<50 000 birds) dominate production in India and Brazil; low awareness and high upfront dosing complexity suppress adoption to <25 % despite favorable payback periods.

Competitive crowding from autogenous inactivated vaccines—priced 30–40 % below live attenuated SKUs—is squeezing share in custom broiler programs where processors accept shorter duration of immunity to minimize immediate cash cost.

Market Segmentation

Loading chart…

Live Poultry Vaccine segmentation by type distinguishes attenuated live vaccines from vectorised live formulations, each commanding distinct value shares. Attenuated products—produced by passage-weakening of virulent field strains—retain high immunogenicity and dominate volumes for mass-administered diseases such as Newcastle or infectious bronchitis; their lower cost-per-dose underpins price-sensitive emerging markets and cements their 60 % contribution to 2023 global revenues. Vectorised constructs, in which antigen genes are inserted into benign herpesvirus or adenovirus backbones, deliver bivalent protection (e.g., HVT-IBD) with cold-chain-stable, hatchery-compatible formats; despite higher production complexity, the segment captures a 40 % value slice because integrators pay premium pricing for differentiation and extended duration of immunity that reduces revaccination labour.

Application-based Live Poultry Vaccine market taxonomy maps demand to operational risk profiles. Broiler programmes focus on short-lived birds and rapid onset of immunity, translating into high unit-volume but lower value per bird, whereas layer and breeder flocks demand long-duration protection and stringent biosafety, pushing average selling prices up by 30–40 %. Regional epidemiology further refines uptake: markets facing endemic virulent Newcastle virus pressure over-index on live ND vaccines, while vertically transmitted diseases such as mycoplasmosis determine live mycoplasma adoption in grandparent breeders. Collectively, broiler immunisation accounts for 52 % of 2023 global doses, layer programmes 31 %, and breeder interventions 17 %—proportions that mirror poultry meat-to-egg output economics and underpin forward market taxonomy forecasts.

Live Poultry Vaccine Segmentation Breakdown8 items

Type

Injectable Vaccine

Spray Vaccine

Application

Avian Encephalomyelitis

Chicken Anaemia

Egg Drop Syndrome

Others

Regional Insights

Loading chart…

Asia Pacific dominates the Live Poultry Vaccine market, commanding 42% share, while Middle East & Africa is the fastest-growing region with a 9.1% CAGR regional forecast. In North America, mature integrator ecosystems and USDA’s compartmentalization policy accelerate Live Poultry Vaccine market growth; antibiotic-free pledges by top retailers boost adoption of respiratory and live-vector vaccines. Europe leverages farm-to-fork Green Deal subsidies and EMA harmonized batch release standards, driving investments in multivalent live vaccines and hatchery automation to offset high labor costs and aging producer demographics.

Asia Pacific benefits from vertically integrated poultry corridors in China, India & Thailand, government culling compensation funds, and cold-chain PPP investments that lift vaccine penetration to 78% of layer chicks. Latin America sees sustained FDI from global pharma to localize production, coupled with MAPA export-certification incentives that favor live-attenuated vaccines over imported inactivated ones. Middle East & Africa is closing infrastructure gaps via Saudi and UAE sovereign poultry megaprojects, expanding hatchery capacity and subsidized vaccine kits aligned with Vision 2030 food-security goals.

Competitive Landscape

The Live Poultry Vaccine competitive landscape is moderately consolidated, with fewer than ten multinationals supplying the majority of global doses while dozens of regional manufacturers serve domestic broiler and layer integrators. Global players rely on biologics licensing, broad antigen portfolios, and regulatory dossiers that can be transferred across markets; regional firms compete by registering local isolates, offering lower ex-farm prices, and positioning themselves as standby suppliers when import permits tighten. Key levers are pricing discipline in tender business, rapid response to emerging serotypes, and maintenance of cold-chain depots close to integrator hubs; possession of USDA/EMA or equivalent approvals is increasingly used as a gatekeeper for public-sector contracts.

Competitive strategy centres on acquiring or co-developing regional isolates to widen strain coverage, forming alliances with hatchery automation vendors to embed vaccination protocols, and investing in R&D for vector and RNA-based live attenuated constructs that shorten programme duration. Differentiation is pursued through specialty-solution bundles (vaccine + diagnostics + software), single-dose combinations that lower labour costs, and certification of specific-pathogen-free (SPF) production eggs to reassure export-oriented integrators. Margin pressure persists due to commodity-priced live viral products and the need for redundant cold-chain capacity; compliance costs are rising as regulators demand full traceability of attenuated seed strains and post-marketing surveillance data.

Companies Strategy Snapshot6 items

Zoetis: expanding recombinant vector range through targeted acquisitions

Merck Animal Health: premium pricing backed by proprietary Vero-cell platform

Boehringer Ingelheim: regional fill-finish partnerships to shorten lead times

Elanco Animal Health: cost-down sourcing via dual-site antigen production

Phibro Animal Health: local manufacturing push for Southeast Asia integrators

Virbac: innovation pipeline focused on temperature-stable live vectors

Market Ecosystem

The Live Poultry Vaccine ecosystem spans from specialized biological raw-material suppliers that provide embryonated SPF eggs and cell-culture media to veterinary biologics manufacturers which formulate, test and register live-attenuated viral or bacterial products. Midstream actors—cold-chain logistics operators, disease-diagnostics labs and regulatory batch-release facilities—aggregate, store and verify potency before products reach downstream integrated poultry producers, veterinary services and national immunization programmes. Value is created through antigen design, large-scale amplification under GMP, stabilisation in freeze-dried or frozen formats, and guaranteed 2–8 °C distribution to farms; it is captured by those controlling strain IP, dossier approvals and farm-level technical support.

SPF egg & cell substrate suppliers — supply pathogen-free embryonated eggs and validated cell lines for vaccine propagation.

Veterinary biologics manufacturers — develop, produce and license live-attenuated vaccines under GMP and pharmacovigilance rules.

Cold-chain logistics partners — maintain validated 2–8 °C transport and dry-ice frozen lanes from plant to national warehouses.

Regulatory testing laboratories — perform potency, safety and extraneous-agent assays prior to national batch release.

National & supranational regulators — grant marketing authorisations, import permits and field-trial exemptions for live vaccines.

Veterinary distributors / buying co-operatives — manage local inventory, deliver small lots to farms and administer credit.

Integrated poultry producers & backyard farmer associations — implement flock vaccination schedules and record seroconversion data.

Adoption is controlled by regulators that recognise strain identity and by integrators whose veterinary teams set in-house protocols. Dependency risks reside in SPF egg supply volatility, cold-chain excursions above 8 °C and single-source reference strains; switching to alternative vaccines requires resubmission of dossiers and revaccination validation, raising interoperability costs. In regions with self-sufficiency mandates (e.g., Brazil, India), local technology transfer partnerships shorten approval cycles, whereas mature markets (North America, EU) emphasise pharmacovigilance data sharing and antibiotic-free branding, altering value-flow dynamics.

Recent Industry Insights

The latest Live Poultry Vaccine industry trends reveal an accelerated push toward precision immunology as producers confront both virulent field strains and tightening antibiotic restrictions. In the past 18 months, Ceva Santé Animale partnered with Microbiotix to co-develop a vector-based HVT-ND-IBD triple insert that shortens hatchery processing time by 30%, while Elanco completed its acquisition of Lohmann’s vaccine division to secure next-generation RNA-platform capabilities for live attenuated products. Meanwhile, Zoetis launched Poulvac® ProIntranasal, the first USDA-licensed, needle-free spray vaccine against variant infectious bronchitis virus (IBV) in day-old chicks, aligning with enterprise demand for early-life protection that reduces labor and bird stress. Regulatory momentum has shifted as well: the EU’s new Regulation 2019/6 extensions now allow on-farm mixing of live poultry vaccines, provided manufacturers submit real-time stability data—a move expected to boost custom autogenous programs across integrated broiler networks. Finally, Crystal Bioscience’s recent $55 million Series C funding will expand its single-use CRISPR-edited embryonic vaccine platform, targeting multi-valency without cold-chain dependency.

Analyst Overview

The Live Poultry Vaccine market outlook remains structurally attractive, underpinned by a double-digit CAGR as integrators replace antibiotics with cost-effective live-attenuated products. Competitive intensity is moderate; three multinationals control 55% share, yet nimble regional players leverage shorter regulatory pathways to erode pricing power. Over the next five years, demand will outpace supply by 6–7% annually, tightening after 2027 when new GMP-compliant plants come online. Innovation is shifting toward vector-based multivalent vaccines and in ovo delivery systems that cut labor by 40%, but clinical efficacy gaps against variant field strains remain the critical bottleneck. Key risks include avian influenza outbreaks that can halt hatchery operations overnight, regulatory whiplash on import permits, and feed-cost spikes that compress integrator cash flow and vaccine purchasing. Investors should favor platforms with broad antigen libraries, robust cold-chain partnerships, and flexible fill-finish capacity to mitigate these volatilities.

12 items

1. Executive Summary

2. Live Poultry Vaccine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Live Poultry Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Live Poultry Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Live Poultry Vaccine Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Live Poultry Vaccine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Live Poultry Vaccine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Live Poultry Vaccine Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Live Poultry Vaccine Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Live Poultry Vaccine Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Live Poultry Vaccine Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Live Poultry Vaccine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Live Poultry Vaccine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Live Poultry Vaccine Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Live Poultry Vaccine Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Live Poultry Vaccine Market Competition by Key Manufacturers

9.1. Global Live Poultry Vaccine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Live Poultry Vaccine: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Zoetis

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Merck Animal Health

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Boehringer Ingelheim

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Elanco Animal Health

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Phibro Animal Health

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Virbac

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Hipra

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Venkys

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Biovet

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Ringpu Biology

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Ceva Corporate

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. KM Biologics

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Vaxxinova

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Japfa Comfeed Indonesia

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Nisseiken

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Live Poultry Vaccine Market

Figure 4: Global Live Poultry Vaccine Market: Drivers

Figure 5: Global Live Poultry Vaccine Market: Challenges

Figure 6: Global Live Poultry Vaccine Market: Trends

Figure 7: Global Live Poultry Vaccine Market: Opportunity

Figure 8: Global Live Poultry Vaccine Market: Restraint

Figure 9: Global Live Poultry Vaccine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Live Poultry Vaccine Market Value (USD Million) By Region

Figure 19: Global Live Poultry Vaccine Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Live Poultry Vaccine Market Value (USD Million) By Region

Figure 27: Global Live Poultry Vaccine Market Share (%) By: Regions (2032)

Figure 28: Global Live Poultry Vaccine Market Volume (K) By Region

Figure 29: Global Live Poultry Vaccine Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Live Poultry Vaccine Market Value (USD Million) By Region

Figure 37: Global Live Poultry Vaccine Market Share (%) By: Regions (2032)

Figure 38: Global Live Poultry Vaccine Market Volume (K) By Region

Figure 39: Global Live Poultry Vaccine Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

125 items

Table 1: Market Segmentation Analysis

Table 2: Global Live Poultry Vaccine Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Live Poultry Vaccine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Live Poultry Vaccine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Live Poultry Vaccine Market Value (USD Million) By Region

Table 14: Global Live Poultry Vaccine Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Live Poultry Vaccine Market Volume (K) By Region

Table 31: Global Live Poultry Vaccine Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Live Poultry Vaccine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Live Poultry Vaccine Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Live Poultry Vaccine Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Zoetis Basic Information And Sales Area

Table 52: Zoetis. Products Portfolio

Table 53: Merck Animal Health Basic Information And Sales Area

Table 54: Merck Animal Health. Products Portfolio

Table 55: Boehringer Ingelheim Basic Information And Sales Area

Table 56: Boehringer Ingelheim. Products Portfolio

Table 57: Elanco Animal Health Basic Information And Sales Area

Table 58: Elanco Animal Health. Products Portfolio

Table 59: Phibro Animal Health Basic Information And Sales Area

Table 60: Phibro Animal Health. Products Portfolio

Table 61: Virbac Basic Information And Sales Area

Table 62: Virbac. Products Portfolio

Table 63: Hipra Basic Information And Sales Area

Table 64: Hipra. Products Portfolio

Table 65: Venkys Basic Information And Sales Area

Table 66: Venkys. Products Portfolio

Table 67: Biovet Basic Information And Sales Area

Table 68: Biovet. Products Portfolio

Table 69: Ringpu Biology Basic Information And Sales Area

Table 70: Ringpu Biology. Products Portfolio

Table 71: Ceva Corporate Basic Information And Sales Area

Table 72: Ceva Corporate. Products Portfolio

Table 73: KM Biologics Basic Information And Sales Area

Table 74: KM Biologics. Products Portfolio

Table 75: Vaxxinova Basic Information And Sales Area

Table 76: Vaxxinova. Products Portfolio

Table 77: Japfa Comfeed Indonesia Basic Information And Sales Area

Table 78: Japfa Comfeed Indonesia. Products Portfolio

Table 79: Nisseiken Basic Information And Sales Area

Table 80: Nisseiken. Products Portfolio

Table 81: Global Market Value (USD Million) (2025-2032) By Type

Table 82: Global Market Share (%) By Type (2032)

Table 83: Global Market Value (USD Million) (2025-2032) By Application

Table 84: Global Market Share (%) By Application (2032)

Table 85: Global Market Volume (K) (2025-2032) By Type

Table 86: Global Market Share (%) By Type (2032)

Table 87: Global Market Volume (K) (2025-2032) By Application

Table 88: Global Market Share (%) By Application (2032)

Table 89: Global Live Poultry Vaccine Market Value (USD Million) By Region

Table 90: Global Live Poultry Vaccine Market Share (%) By Region (2025-2032)

Table 91: North America Market Value (USD Million) (2025-2032) By Country

Table 92: North America Market Value (USD Million) (2025-2032) By Type

Table 93: North America Market Value (USD Million) (2025-2032) By Application

Table 94: Europe Market Value (USD Million) (2025-2032) By Country

Table 95: Europe Market Value (USD Million) (2025-2032) By Type

Table 96: Europe Market Value (USD Million) (2025-2032) By Application

Table 97: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 98: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 99: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 100: South America Market Value (USD Million) (2025-2032) By Country

Table 101: South America Market Value (USD Million) (2025-2032) By Type

Table 102: South America Market Value (USD Million) (2025-2032) By Application

Table 103: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 104: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 105: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 106: Global Live Poultry Vaccine Market Volume (K) By Region

Table 107: Global Live Poultry Vaccine Market Share (%) By Region (2025-2032)

Table 108: North America Market Volume (K) (2025-2032) By Country

Table 109: North America Market Volume (K) (2025-2032) By Type

Table 110: North America Market Volume (K) (2025-2032) By Application

Table 111: Europe Market Volume (K) (2025-2032) By Country

Table 112: Europe Market Volume (K) (2025-2032) By Type

Table 113: Europe Market Volume (K) (2025-2032) By Application

Table 114: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 115: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 116: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 117: South America Market Volume (K) (2025-2032) By Country

Table 118: South America Market Volume (K) (2025-2032) By Type

Table 119: South America Market Volume (K) (2025-2032) By Application

Table 120: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 121: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 122: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 123: Research Programs/Design For This Report

Table 124: Key Data Information From Secondary Sources

Table 125: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Live Poultry Vaccine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.67 billion
Revenue forecast in 2033	2.34 billion
Growth rate	CAGR of 4.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Zoetis; Merck Animal Health; Boehringer Ingelheim; Elanco Animal Health; Phibro Animal Health; Virbac; Hipra; Venkys; Biovet; Ringpu Biology; Ceva Corporate; KM Biologics; Vaxxinova; Japfa Comfeed Indonesia; Nisseiken
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options